Zepbound vs. Wegovy: Which Drug is Best for Obstructive Sleep Apnea (OSA) Patients?

For patients with obstructive sleep apnea and obesity, Zepbound is the first and only medication approved by the FDA specifically to treat OSA. While Wegovy is an effective weight-loss drug, its benefits for sleep apnea are not its primary FDA-approved purpose. Choosing between them depends on your specific health goals .

If your main concern is treating moderate-to-severe sleep apnea, Zepbound has the most direct evidence. If your focus is overall weight loss and improving heart health, Wegovy remains a powerful option.

Key Takeaways

• Zepbound is FDA-approved for OSA, making it the first medication specifically approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
• Wegovy helps OSA indirectly through significant weight loss but is not officially approved for this condition.
• Zepbound leads to greater weight loss, with studies showing an average of 20.2% body weight reduction compared to 13.7% with Wegovy.
• Both drugs are powerful tools that require a prescription and medical supervision due to potential side effects and important safety warnings.
• These medications work alongside your CPAP machine, they are not a replacement for your existing sleep apnea therapy unless your doctor advises otherwise.

What Should Patients Know About Zepbound vs Wegovy for Sleep Apnea?

It is important to know the basic facts about these two medications. While both are weekly injections that have transformed weight management, they are approved for different uses.

The core difference lies in their official indications. In December 2024, the U.S. Food and Drug Administration (FDA) approved Zepbound as the first medication for treating moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy does not have this specific approval.

The table below summarizes their key profiles:

Both medications work by mimicking hormones in your gut that regulate appetite and blood sugar. Zepbound targets two hormone pathways (GIP and GLP-1), while Wegovy targets one (GLP-1). This key difference in mechanism contributes to their varying levels of effectiveness for weight loss and related conditions.

How Does Zepbound Treat Obstructive Sleep Apnea Beyond Weight Loss?

Zepbound's approval for sleep apnea is not a coincidence. It is based on robust clinical evidence showing it directly improves the breathing disruptions that define OSA.

The FDA approval was grounded in two major Phase 3 clinical trials known as SURMOUNT-OSA. These studies involved 469 adults with obesity and moderate-to-severe OSA. One trial included people who could not or would not use a CPAP machine, and the other included those who were already using CPAP therapy .

After 52 weeks, the results were significant. Participants taking Zepbound experienced about 25 to 29 fewer breathing disruptions per hour of sleep. Those taking a placebo only saw a reduction of 5 to 6 events per hour . This means Zepbound led to a clinically meaningful improvement in the Apnea-Hypopnea Index (AHI), which is the main measure of OSA severity.

Importantly, a large number of patients saw their condition improve dramatically. The studies found that 42% to 50% of participants on Zepbound achieved disease remission, meaning their OSA became mild or resolved entirely. In the placebo group, only 14% to 16% saw this level of improvement .

While weight loss is a critical part of how Zepbound works, the improvement in AHI is likely a direct result of this reduction in body weight. By reducing fat mass, including around the upper airway, the medication helps prevent the airway collapse that causes breathing pauses during sleep .

Can Wegovy Help Reduce Nighttime Breathing Problems in Sleep Apnea?

Even without an official FDA approval for OSA, Wegovy can still be a valuable tool for managing the condition. This is because obesity is the leading risk factor for sleep apnea, and effective weight loss often leads to improvement.

A large retrospective study published in 2025 offers compelling real-world evidence. The study analyzed health insurance claims data from tens of thousands of patients with obesity. It compared those who used anti-obesity medications, including Wegovy and Zepbound, to those who did not .

The findings were clear: patients using these medications had a 40% lower likelihood of being diagnosed with obstructive sleep apnea compared to those not on the drugs . This shows a strong association between the use of Wegovy and a reduced risk of developing OSA.

Furthermore, a subgroup analysis within the study suggested that Wegovy users had a slightly higher incidence of OSA (3.18%) compared to Zepbound users (2.65%). However, after adjusting for other factors, this difference was not statistically significant. This indicates that while Wegovy is powerfully effective, Zepbound may have a slight edge in reducing OSA risk.

The takeaway is that Wegovy, through substantial weight loss, can indirectly lead to major improvements in sleep apnea severity. For many patients, losing weight can reduce the number of breathing events they experience each night and improve their overall sleep quality.

How Do Zepbound and Wegovy Compare for Weight Loss and Breathing Improvements?

When deciding between two medications, seeing a direct comparison of their results is very helpful. A head-to-head study published in the New England Journal of Medicine in 2025 provides the clearest picture yet.

In this 72-week study, patients taking Zepbound lost an average of 20.2% of their body weight. This translates to about 50 pounds. Patients taking Wegovy also lost a significant amount of weight, averaging 13.7% of their body weight, or about 33 pounds .

The study also showed that nearly a third (32%) of people on Zepbound lost at least a quarter of their body weight, compared to 16% of those on Wegovy. This data confirms that Zepbound leads to greater weight reduction on average.

But what does this mean for breathing and other health benefits? The table below compares key outcomes:

Both medications led to improvements in other health markers like blood sugar and cholesterol. However, the study noted that the greater improvement in systolic blood pressure seen with Zepbound could be clinically important for reducing the risk of cardiovascular events .

Which GLP-1 Medication Is Better for OSA Patients, Zepbound or Wegovy?

So, which one is the better choice for you? Based on the current evidence, Zepbound has a stronger case for being the preferred drug for treating obstructive sleep apnea in patients with obesity.

The reasons are clear:

• FDA Approval: Zepbound is the only one with official FDA approval for this specific condition .
• Proven Efficacy: Its ability to reduce breathing disruptions and even lead to disease remission is backed by gold-standard clinical trials .
• Greater Weight Loss: Its superior weight loss results likely contribute to more significant improvements in OSA severity .

However, "better" can depend on your individual circumstances. Wegovy is still a highly effective medication for weight loss and has its own important FDA approval for reducing the risk of major heart problems like heart attack and stroke in people with heart disease and obesity. If you have both OSA and significant cardiovascular concerns, your doctor might consider this an important factor.

The choice is not one-size-fits-all. As one expert noted, "We're going to need to use them all just because we have so many patients who need treatment". The best medication for you will depend on your overall health profile, how you tolerate the side effects, and your specific health goals.

How Should You Talk to Your Doctor About Using GLP-1 Drugs for Sleep Apnea?

Having an informed conversation with your doctor is the most critical step. Here is how you can prepare.

First, come ready to discuss your health history. Your doctor will need to know your body mass index (BMI), your official OSA diagnosis and its severity (like your AHI score from a sleep study), and any other health conditions you have. Be sure to mention if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, as these are contraindications for Zepbound .

Next, ask targeted questions. You can use the following as a guide:

• "Based on my sleep apnea and weight, am I a good candidate for Zepbound or Wegovy?"
• "How will we monitor my progress on the medication?"
• "What should I do about side effects like nausea?"
• "If I start one of these medications, can I stop using my CPAP machine?" (The answer is likely no—these medications are a supplement to, not a replacement for, existing therapies .)

Finally, be prepared for insurance considerations. Zepbound's list price is over $1,000 per fill. While its FDA approval for OSA may help with coverage, many insurance plans require a complex prior authorization process. Your doctor's office may need to submit a detailed letter of medical necessity. Be patient and know that having a dedicated staff at your clinic to handle this can make a big difference .